Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 4Phase NA 2Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 18Recruiting 11Unknown 6Not yet recruiting 6Terminated 2Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 1FED 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 192Neoplasms 148Prostatic Neoplasms 101Lung Neoplasms 90Carcinoma, Non-Small-Cell Lung 62Colorectal Neoplasms 59Head and Neck Neoplasms 52Pancreatic Neoplasms 46Carcinoma, Hepatocellular 44Rectal Neoplasms 42Brain Neoplasms 41Multiple Myeloma 40Colonic Neoplasms 37Esophageal Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 31Neoplasm Metastasis 30Leukemia, Myeloid, Acute 30Ovarian Neoplasms 29Lymphoma, Non-Hodgkin 29Leukemia 29Lymphoma 28Motor Activity 26Hodgkin Disease 24Uterine Cervical Neoplasms 23Carcinoma, Renal Cell 23Pain 22Lymphoma, Follicular 22Depression 22Leukemia, Lymphocytic, Chronic, B-Cell 21Glioma 21

Interventions

Immunoglobulins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Terminated × Myasthenia Gravis × Clear all
NCT06965309 2026-02-12

Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)

Shenzhen MagicRNA Biotechnology Co., Ltd

Phase NA Terminated
9 enrolled

Myasthenia Gravis

NCT00004682 2015-03-25

Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis

FDA Office of Orphan Products Development

Phase NA Terminated
100 enrolled

Mental Disorders, Myasthenia Gravis, Neurologic Manifestations, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡